Research Analysts Offer Predictions for Indivior Q3 Earnings

Indivior PLC (NASDAQ:INDV) – Stock analysts at Northland Capmk raised their Q3 2025 earnings estimates for Indivior in a report released on Thursday, April 24th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.25 per share for the quarter, up from their prior estimate of $0.23. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. Northland Capmk also issued estimates for Indivior’s Q4 2025 earnings at $0.27 EPS and FY2026 earnings at $1.35 EPS.

INDV has been the topic of several other research reports. RODMAN&RENSHAW raised shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Piper Sandler cut their price target on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

Indivior Stock Performance

Shares of Indivior stock opened at $11.56 on Friday. The business’s 50 day moving average price is $9.48 and its 200 day moving average price is $10.32. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -33.03 and a beta of 0.93. Indivior has a one year low of $7.33 and a one year high of $18.59.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analysts’ expectations of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Indivior during the fourth quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior during the 4th quarter worth approximately $56,000. Lazard Asset Management LLC acquired a new stake in Indivior in the 4th quarter valued at approximately $57,000. Schaper Benz & Wise Investment Counsel Inc. WI purchased a new stake in Indivior in the first quarter valued at approximately $95,000. Finally, Stifel Financial Corp acquired a new position in Indivior during the third quarter worth $100,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.